title: Management of Metastatic Pancreatic Adenocarcinoma.
abstract: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal and clinically challenging malignancies to treat, with an estimated 5-year survival rate of approximately 7%. At the time of initial presentation, a majority of patients have metastatic disease. The median overall survival in these patients with good performance status is 8.5 to 11.1 months and in patients with significantly impaired performance status, even less. Strategies to integrate novel agents with traditional cytotoxic therapies are under investigation and hold promise for improving outcomes in patients with metastatic PDAC. This article focuses on the current management options and novel therapeutics for metastatic PDAC.
authors.affiliation: Department of Medicine, Icahn School of Medicine at Mount Sinai, 1 Gustave Levy Pl, New York, NY 10029, USA; Department of Medicine, Mount Sinai St. Luke's-West Hospital Center, 1111 Amsterdam Avenue, New York, NY 10025, USA.
authors.forename: Ahmad R
authors.initials: AR
authors.lastname: Cheema
authors.affiliation: Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, Office 1021, New York, NY 10065, USA; Weill Cornell Medical College, 1300 York Avenue, New York, NY 10065, USA. Electronic address: oreillye@mskcc.org.
authors.forename: Eileen M
authors.initials: EM
authors.lastname: O'Reilly
mesh_terms: D000230:Adenocarcinoma / Q000556:secondary / Q000628:therapy*; D003131:Combined Modality Therapy; D019468:Disease Management; D006801:Humans; D009362:Neoplasm Metastasis; D010190:Pancreatic Neoplasms / Q000473:pathology / Q000628:therapy*
keywords: FOLFIRINOX; Gemcitabine; Immune therapy; Metastatic disease; Nab-paclitaxel; Pancreatic cancer; Targeted agents